

Item 1. Cover Page

Part 2B of Form ADV: Brochure Supplement

Birchview Capital, LP

688 Pine Street, Suite 2D
Burlington, VT 05401

Contact:
(802) 923-3826

Matthew Strobeck

April 2024

This Brochure Supplement provides information about Matthew Strobeck that supplements the Birchview Capital, LP (“Birchview” or the “Firm”) Form ADV Part 2A Brochure (the “Brochure”), which you should have received. Please contact us at (802)-923-3826 if you did not receive the Brochure or if you have any questions about the contents of this Brochure Supplement.

Additional information about the Firm is also available on the SEC’s website at www.adviserinfo.sec.gov. Matthew Strobeck’s CRD number is: 5522663.

Item 2. Educational Background and Business Experience

Matthew Strobeck, Ph. D.

Born: 12/10/72

Educational Background:

St. Lawrence University, B.S.

University of Cincinnati, Ph.D.

Harvard University-MIT Health Sciences Technology Program, S.M.

MIT Sloan School of Management, S.M.

Business Background:

Dr. Strobeck is currently the Managing Partner of Birchview. From April 2012 to February 2014, Dr. Strobeck managed the Firm as a family office. From June 2008 to October 2011, Dr. Strobeck was a Partner, Member of the Management Committee and Member of the Advisory Board of Westfield Capital Management, an investment firm based in Boston. From May 2004 to June 2008, Dr. Strobeck was an investment analyst and member of the Investment Committee at Westfield Capital. Dr. Strobeck previously served as a Director of Collegium Pharmaceuticals, Precision Dermatology, Santarus, Metabolix/Yield10, Tepha Medical, and the Schuler Education Foundation. He currently serves on the Boards of Accelerate Diagnostics, Inc., Biodesix, Inc., Quidel Corporation, and Monteris Medical, Inc.

Item 3. Disciplinary Information

Dr. Strobeck has no legal or disciplinary events to report that would be material to a client's or prospective client's evaluation of Dr. Strobeck.

Item 4. Other Business Activities

Dr. Strobeck is not registered and does not have an application pending to register as (i) a broker-dealer or registered representative of a broker-dealer, or (ii) futures commission merchant, commodity pool operator, commodity trading advisor, or an associated person of any of the foregoing.

Dr. Strobeck is a Director of the following companies:

- Accelerate Diagnostics Inc. (public)
- Biodesix Inc. (public)
- Quidel Corporation (public)
- Monteris Medical, Inc. (private)

Item 5. Additional Compensation

The table below shows the form of compensation Dr. Strobeck has received from each company where he is a member of the Board of Directors. His director compensation from any portfolio company of Birchview's various advisory clients is credited against the management fees charged by Birchview Capital to such clients.

Please also see Item 4 of the Brochure for further detail regarding the method by which management fees charged to Birchview's clients are offset by any such director compensation received by Dr. Strobeck.

Company	Form of Compensation
Accelerate Diagnostics, Inc (public)	Options
Biodesix, Inc (public)	Options, and Restricted Stock Units
Quidel Corporation (public)	Options, Cash and Restricted Stock Units
Monteris Medical, Inc. (private)	Options

Dr. Strobeck also invests personal assets in certain accounts managed by Birchview and may receive investment income or losses from such investments.

Item 6. Supervision

Dr. Strobeck is the Chief Investment Officer and Managing Partner of Birchview. He is required to conform to Birchview's overall compliance program, including its Compliance Manual and Code of Ethics. Jack Trottier Chief Compliance Officer of Birchview is responsible for ensuring that all Birchview employees, including Dr. Strobeck, abide by Birchview's compliance program. Mr. Trottier may be reached at (802)-923-3826.